Alzheimer’s Disease Biomarkers Discovered by SELDI-TOF

Bio-Rad Laboratories, Inc., a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the availability of a technical paper (bulletin 5695) entitled, “Identification of a Panel of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease by SELDI-TOF-MS”, that describes how SELDI-TOF was used to discover potential Alzheimer’s Disease biomarkers.

The paper describes how Bio-Rad’s ProteinChip^® SELDI system was used to analyze cerebrospinal fluid (CSF) samples from large groups of patients with and without Alzheimer’s Disease (AD) and those with and without another form of dementia called frontotemporal dementia (FTD).

In the study, Bio-Rad researchers discovered and verified a total of 15 potential biomarkers that are capable of distinguishing AD patients from healthy controls. Moreover, seven of these markers are capable of further distinguishing AD patients from FTD patients.

The work presented confirms that protein profile changes in the brain of AD patients are reflected in the CSF and these proteins can be analyzed directly, quickly, and reproducibly with SELDI technology. Further, the results also demonstrate that the use of multiple ProteinChip SELDI chromatographic array types was instrumental to the discovery and verification process as the 15 potential biomarkers were discovered using three different array chemistries.

Availability
The Alzheimer’s Disease biomarker technical paper (bulletin 5695) is available from any Bio Rad sales office or can be downloaded from the Bio-Rad web site by visiting the article webpage.